Ipilimumab and dabrafenib: predicted versus actual analysis
Page last updated: 4 March 2016
Drug utilisation sub-committee (DUSC)
October 2015
Abstract
Purpose
To review the predicted versus actual use of ipilimumab and dabrafenib for unresectable melanoma, as requested by DUSC at its June 2014 meeting. The analysis of ipilimumab is a 24 month review; the analysis of dabrafenib is a 12 month review.
Listing on the Pharmaceutical Benefits Scheme (PBS)
- Ipilimumab, PBS listed 1 August 2013
- Dabrafenib, PBS listed 1 December 2013
Ipilimumab and dabrafenib are listed for unresectable Stage III or Stage IV malignant melanoma. For dabrafenib, the condition must have a BRAF V600 mutation and the patient must have a WHO performance status of 2 or less. The condition must not have been treated previously with PBS subsidised therapy; or the patient must have developed intolerance to another BRAF inhibitor of a severity necessitating permanent treatment withdrawal. For continuing treatment, patients must have stable or responding disease. See the PBS website for the full restriction.
Data Source / methodology
Prescription data were extracted from the Department of Human Services (DHS) prescription database for the period August 2013 to April 2015, inclusive.
Key Findings
- Since listing, 2,484 patients have been treated with dabrafenib or ipilimumab. In
2014:
-1,642 patients were dispensed at least one prescription of dabrafenib or ipilimumab;
-1,467 of these patients were starting treatment with dabrafenib or ipilimumab for the first time. Of these, 712 patients started treatment with dabrafenib and 755 patients started treatment with ipilimumab. - The number of new patients initiating dabrafenib and ipilimumab per month is similar.
